The response to drug treatment in asthma is a complex trait and is markedly variable even in patients with apparently similar clinical features. Pharmacogenomics is a study of variations of human genome characteristics as related to drug response. A traditional candidate-gene approach and genome-wide association studies have provided an increasing list of genes and variants that was associated with asthma medications. However, as phenotypic variations arises from a network of complex interactions among genetic and environmental factors, rather than individual genes, a multidisciplinary, system-level approach is required in order to understand the interrelationships among these factors. Systems biology that studies organisms as integrated and interacting networks of genes, proteins and biochemical reactions can contribute to this. It is likely that the combination of network modeling, functional validation, and integrative -Omics will be needed to move asthma pharmacogenomics closer to clinical relevance. 
Given that a response to inhaled β2-agonists in asthma is a complex phenotype, they selected targets by screening variants in the β2 adrenergic pathways.
16 THRB rs892940 They hypothesized that genes regulated by in vitro exposure to isoproterenol (β2-agonist) would be good candidates and tested transcription factors genes.
17
Inhaled corticosteroids CRHR1 rs242941, rs1876828, rs2236647, rs6591838
They focused on the endogenous glucocorticoids biosynthesis pathway in selecting optimal targets.
18
TBX1 rs2240017 (His33Glu) They showed that drugs could interact with genes that are not in the direct metabolic or signaling pathway of the drug.
19
Leukotriene modifier ALOX5 Promoter repeat rs4987105, rs4986832
They focused on the leukotriene biosynthesis pathway in selecting optimal targets. 20,21
This study consisted of 1,644 asthma subjects from six trial cohorts and two replication cohorts.
22
SLC22A15 rs1281748, rs1281743 A total of 2,313 Latino children with asthma was enrolled in the primary and replication study. They suggested that rare variation contributes to a differential drug response.
23
Inhaled corticosteroids GLCCI1 rs37972 One hundred and eighteen probands from the CAMP trial and 935 asthma subjects from four additional replication cohorts.
This study consisted of 408 asthma patients from the CAMP, ACRN, and CARE trial and a replication cohort consisting of 407 asthma patients.
25
FBXL7 rs10044254 This is the first GWAS for asthma symptom responses to ICS and they suggested that there may be a specific genetic mechanism regulating symptomatic response in children that does not carry over to adults.
26
Leukotriene modifier ALOX5AP rs17238738 This is the first GWAS of leukotriene modifier in asthma and they showed that previously unreported genes and loci within pathways for leukotriene both production and response are implicated in therapeutic responsiveness.* RGS13 rs4147217
CAMP, childhood asthma management program; ACRN, asthma clinical research network; CARE, childhood asthma reserch and education; ICS, inhaled corticosteroid; GWAS, genome wide association study. 
47
Inhaled corticosteroids TNC rs7850103 Using an integrative approach, they reported that drug specific eQTL associated with change in TNC expression following dexamethasone stimulation in cultured human osteoblast-like cells were also associated with clinical response to ICS in asthma.
49

SPATA20
rs6504666, rs1380657
They conducted an eQTL analysis in dexamethasone treated and untreated lymphoblast cell lines obtained from asthmatic subjects in the CAMP trial and tested the associations of eQTL with longitudinal change in airway responsiveness to methacholine on ICS.
50
SNP, single nucleotide polymorphism; BDR, bronchodilator response; eQTL, expression quantitative trait loci; ICS, inhaled corticosteroid; CAMP, childhood asthma management program.
